372320 — Curocell Income Statement
0.000.00%
- KR₩445bn
- KR₩456bn
Annual income statement for Curocell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | — | — | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 36 | 0 | 0 | 0 |
Cost of Revenue | ||||
Gross Profit | 21.4 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Total Operating Expenses | 10,621 | 15,287 | 21,425 | 31,130 |
Operating Profit | -10,585 | -15,287 | -21,425 | -31,130 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -7,699 | -53,576 | -38,885 | -29,664 |
Provision for Income Taxes | ||||
Net Income After Taxes | -7,699 | -53,576 | -38,885 | -29,575 |
Net Income Before Extraordinary Items | ||||
Net Income | -7,699 | -53,576 | -38,885 | -29,575 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -7,699 | -53,576 | -38,885 | -29,575 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -566 | -3,936 | -2,857 | -2,499 |
Dividends per Share |